Monitoring of minimal residual disease is a key method for detecting potential acute myeloid leukaemia relapse. Here, the authors developed a longitudinal mutation burden monitoring strategy using ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Hematologic oncologist Eytan Stein (shown here with nurse practitioner Coleen Ranaghan) has led the development of several new drugs for acute myeloid leukemia. Acute myeloid leukemia (AML) is one of ...

Harry Erba, MD, PhD, professor of medicine at Duke Cancer Institute, chair of the SWOG Leukemia Committee, and co-chair of ...

Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are cancers that originate from a type of white blood cell. AML features a rapid onset, and CML is slower to progress. Leukemia is a ...

Jerry Cheng, MD, Fellow, Department of Pediatrics, Mattel Children's Hospital at University of California at Los Angeles Kathleen M. Sakamoto, MD, PhD, Associate Professor, Departments of ...

If left untreated, MDS can progress to acute myeloid leukemia (AML), particularly ... on the pivotal role of mutated DDX41 protein in the pathogenesis of Myelodysplastic Syndrome (MDS), a form ...

ALL = Acute lymphoblastic leukemia; AML = Acute myeloid leukemia; FTI = Farnesyltransferase inhibitor; HDAC = Histone deacetylase; NF = Nuclear factor; Ph = Philadelphia chromosome; TKI = Tyrosine ...

I am a physician-scientist focused on researching and treating blood and bone marrow cancers, including acute myeloid leukemia and the chronic myeloproliferative neoplasms polycythemia vera, essential ...

Patients with newly diagnosed acute myeloid leukemia are extremely ill at diagnosis and are at risk of life-threatening complications before initiating treatment,” said Dr. Nathan Montgomery ...